TABLE 4.
Univariate analysis of predictors for SAH after endovascular therapy.
| SAH (n=20) |
Non SAH (n=139) |
Total (n=159) |
P | |
|---|---|---|---|---|
| Mean Age, years±SD | 63.9±18.3 | 67.8±18.3 | 67.3±18.3 | 0.37 |
| Female, % | 55.0% (11/20) | 54.7% (76/139) | 54.7% (87/159) | >0.99 |
| Hypertension | 85.0% (17/20) | 63.2% (86/136) | 66.0% (103/156) | 0.08 |
| Diabetes mellitus | 35.0% (7/20) | 14.7% (20/136) | 17.3% (27/156) | 0.05 |
| Hyperlipidemia | 20.0% (4/20) | 32.4% (44/136) | 30.8% (48/156) | 0.31 |
| Coronary artery disease | 25.0% (5/20) | 26.5% (36/136) | 26.3% (41/156) | >0.99 |
| Current smoking | 20.0% (4/20) | 9.6% (13/136) | 10.9% (17/156) | 0.24 |
| Atrial fibrillation | 55.0% (11/20) | 44.9% (61/136) | 46.2% (72/156) | 0.47 |
| Peripheral vascular disorder |
10.0% (2/20) | 6.6% (9/136) | 7.1% (11/156) | 0.63 |
| History of stroke or TIA | 20.0% (4/20) | 18.4% (25/136) | 18.6% (29/156) | 0.77 |
| Proximal stenosis | 10.0% (2/20) | 8.0% (11/137) | 8.3% (13/157) | 0.67 |
| Premorbid medications | 35.0% (7/20) | 41.2% (56/136) | 40.4% (63/156) | 0.64 |
| Glucose (mg/dL) | 133±30.4 | 136±50.5 | 135.8±47.9 | 0.81 |
| Platelets (count) | 217±65.4 | 221±67.2 | 220±66.7 | 0.81 |
| Hematocrit | 38.8±5.0 | 39.3±5.0 | 39.2±5.0 | 0.73 |
| Systolic blood pressure (mmHg) |
154±33.6 | 162±33.3 | 161±33.3 | 0.32 |
| Diastolic blood pressure (mmHg) |
84±15.6 | 85.6±19.3 | 85±18.8 | 0.72 |
| Baseline NIHSS score | 17.5±7.1 | 17.1±7.1 | 17.2±7.1 | 0.83 |
| Symptom onset to groin puncture (h) |
5.18±1.91 | 5.42±2.75 | 5.39±2.65 | 0.82 |
| Mean procedure duration (h) |
1.86±0.66 | 1.83±0.71 | 1.83±0.70 | 0.84 |
| Attempts to remove clot, mean±SD |
2.89±1.28 | 3.03±1.65 | 3.01±1.60 | 0.97 |
| Type of occlusion | ||||
| ICA | 20.0% (4/20) | 26.6% (37/139) | 25.8% (41/159) | 0.60 |
| MCA proximal M1 | 5.0% (1/20) | 23.7% (33/139) | 21.4% (34/159) | 0.08 |
| MCA distal M1 | 60.0% (12/20) | 28.1% (39/139) | 32.1% (51/159) | 0.006 |
| MCA M2 | 15.0% (3/20) | 13.7% (19/139) | 13.8% (22/159) | >0.99 |
| Vertebrobasilar | 0% (0/20) | 7.2% (10/139) | 6.3% (10/159) | 0.37 |
| ASITN collateral flow grade |
||||
| 3–4 | 40% (8/20) | 39.6% (55/139) | 39.6% (63/159) | >0.99 |
| 1–2 | 45% (9/20) | 51.1% (71/139) | 50.3% (80/159) | 0.64 |
| 0 | 15% (3/20) | 9.4% (13/139) | 10.1% (16/159) | 0.43 |
| Final AOL II/III flow | 60.0% (12/20) | 72.7% (101/139) | 71.1% (113/159) | 0.29 |
| Final TIMI flow | ||||
| 0–1 | 40.0% (8/20) | 27.3% (38/139) | 28.9% (46/159) | 0.29 |
| 2 | 50.0% (10/20) | 43.9% (61/139) | 44.7% (71/159) | 0.64 |
| 3 | 10.0% (2/20) | 28.8% (40/139) | 26.4% (42/159) | 0.10 |
| Primary IA therapy | 10.0% (2/20) | 20.9% (29/139) | 19.5% (31/159) | 0.37 |
| Primary mechanical thrombectomy |
90.0% (18/20) | 79.1% (110/139) | 80.55% (128/159) | 0.37 |
| Pure MERCI | 30.0% (6/20) | 44.6% (62/139) | 42.8% (68/159) | 0.24 |
| MERCI+IV/IA | 30.0% (6/20) | 23.7% (33/139) | 24.5% (39/159) | 0.59 |
| MERCI+intracranial angioplasty |
20.0% (4/20) | 3.6% (5/139) | 5.7% (9/159) | 0.02 |
| MERCI+microsnare | 5.0% (1/20) | 3.6% (5/139) | 3.8% (6/159) | 0.56 |
| Procedure-related vessel dissection |
10.0% (2/20) | 2.2% (3/137) | 3.2% (5/157) | 0.12 |
| Procedure-related vessel perforation |
25.0% (5/20) | 1.5% (2/137) | 4.5% (7/157) | 0.0004 |
| IV or IA lytic use | 50.0% (10/20) | 46.0% (64/139) | 46.5% (74/159) | 0.81 |